Parasitic Clearance and Recurrence Rates Among Patients With Vivax Malaria
Status:
Unknown status
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
This research is intended to study the efficacy of CQ alone for P.vivax infection and also to
study the recurrence rate among patients with P.vivax on standard dose of CQ and PQ. For this
study, PQ will be withheld for 28 days so as to study the efficacy of CQ alone since masking
effect over one another was found when CQ is given with PQ. So the investigators are not sure
whether the recurrence is due to resistance to CQ or CQ concentration in blood is below
therapeutic level or it is due to PQ is in inadequate dose. From this study the investigators
will get findings like may be CQ is still working for P.vivax or no longer working for
P.vivax due to resistance developed by P.vivax parasites. So for P.vivax which is not
responding to CQ therapy, the investigators will go for second line treatment with ACT in a
similar fashion as it is given for P. falciparum infection in Bhutan. And if the
investigators find CQ is still working for P.vivax infection, the next level of study will be
to compare higher dose of PQ with standard dose of PQ ( as practiced now) in lieu of bringing
down the relapse rates in P. vivax infection.
Details
Lead Sponsor:
Ministry of Health, Bhutan
Collaborators:
Asia Pacific Malaria Elimination Network Menzies School of Health Research